The two most-searched recovery peptides on the consumer internet. Both have extensive animal research. Both have almost no published human clinical trials. Both are sold by the same vendors, often pre-mixed under the brand name "Wolverine." Most pages comparing them gloss the most important fact — which is that gym-forum confidence about either one is running far ahead of the human evidence.
Both peptides have impressive animal data and almost zero published human clinical trials. BPC-157 has a stronger animal-model record for tendon, ligament, and gut healing, with mechanism studies pointing at angiogenesis (new blood vessel growth) and growth-factor signaling. TB-500 has a stronger record for cardiac muscle repair and broad wound healing, with a different mechanism (actin sequestration that helps cells migrate to injury sites).
If you're going to be honest about it: "BPC-157 helps tendons" is a reasonable summary of animal studies. "BPC-157 will help your tendon" is an extrapolation across a species gap that no published human trial supports. Same goes for TB-500. Both peptides also share the same regulatory status as of May 2026 — removed from FDA Category 2 in April 2026, awaiting PCAC review.
One critical practical difference: TB-500 is on the World Anti-Doping Agency's prohibited list. BPC-157 is not. If you compete in any WADA-tested sport, even a single use of TB-500 ends your eligibility. This isn't a small distinction.
When you compare the two peptides on what's actually been studied, the visual is striking — and it's the same shape for both. Mountain of animal research. Cliff to almost nothing on the human side.
Approximate published peer-reviewed counts as of 2025. PubMed search of "BPC-157" returns ~150 papers, almost entirely animal/in-vitro. PubMed search of "thymosin beta-4" returns ~600+ papers across the broader research field, with roughly 80 directly relevant to the wound-healing / repair claims; about 5 small Phase 1/2 human trials exist for full thymosin beta-4 (e.g., RGN-352 in cardiac, RGN-259 in dry eye), but trials of synthetic "TB-500" specifically are essentially nonexistent.
The mechanisms overlap meaningfully (both promote new blood-vessel formation, both modulate inflammation) but are mechanistically distinct enough that the case for stacking them isn't crazy — even if it's not formally proven.
BPC-157 is a 15-amino-acid synthetic peptide derived from a protein found naturally in human gastric juice. The "Body Protection Compound" name comes from its proposed role in protecting the gastric lining. The mechanisms reported in animal studies cluster around three things:
1. Angiogenesis — new blood vessel formation. Animal models consistently show BPC-157 increasing capillary growth at injury sites. More blood supply means more oxygen and nutrient delivery to healing tissue. This is the most-replicated finding across the BPC-157 literature.
2. Growth-factor and growth-hormone-axis signaling. Animal data suggests BPC-157 upregulates expression of vascular endothelial growth factor (VEGF) and may influence growth hormone receptor expression. These are the molecular signals that tell tissue to repair and grow.
3. Modulation of nitric oxide and dopaminergic systems. Less prominent in marketing but appears repeatedly in mechanism papers. Suggests BPC-157 has effects beyond pure tissue repair — mood and gut function are both reported endpoints in animal studies.
TB-500 is a synthetic peptide based on a 4-amino-acid fragment of Thymosin Beta-4, a 43-amino-acid protein found naturally in nearly every cell of the body. The full Thymosin Beta-4 protein is what's been studied in clinical trials (under research names like RGN-352 and RGN-259); the "TB-500" sold in the research peptide market is a much shorter synthetic that approximates the active region.
Its primary mechanism is fundamentally different from BPC-157:
1. Actin sequestration. Thymosin Beta-4 is the major actin-binding protein in cells. Actin is the cytoskeletal protein that allows cells to change shape and move. By regulating actin availability, TB-500 enables cells — particularly stem cells and progenitor cells — to migrate to injury sites.
2. Angiogenesis. Like BPC-157, TB-500 promotes new blood vessel formation. This is where the mechanisms overlap.
3. Anti-inflammatory effects. Reduces pro-inflammatory cytokines in animal injury models. Different molecular pathway than BPC-157's anti-inflammatory effects, but similar net result.
If you visualize tissue repair as a construction project: BPC-157 is the pipeline that brings raw materials to the site. Better blood supply, more growth signal. TB-500 is the dispatch system that gets the construction crew there. Better cell migration, more workers. The "Wolverine" stack pairs both because in theory they work on different parts of the repair process. In practice — this is the editorial point most articles skip — no human study has ever tested whether stacking them produces a better outcome than either alone. That claim is purely mechanistic theory.
Mechanism, evidence, sport-legality, regulatory status, and the practical reality — all in one table.
| BPC-157 | TB-500 | |
|---|---|---|
| Full name / origin | Body Protection Compound — synthetic 15-amino-acid peptide derived from a human gastric juice protein | Synthetic peptide based on a fragment of Thymosin Beta-4, a 43-aa protein found in nearly every cell |
| Primary mechanism | Angiogenesis + growth factor signaling (VEGF, GH axis) | Actin sequestration → enables cell migration; angiogenesis |
| Half-life | ~30 minutes (estimated; pharmacokinetics studies are limited) | Several hours in blood; tissue residence longer |
| Routes of administration | Oral, subcutaneous, or intramuscular injection (research only) | Subcutaneous or intramuscular injection (research only) |
| Animal evidence base | ~150 published peer-reviewed studies. Strongest record: tendon healing, gut/stomach ulcer healing, ligament repair, neural protection. | ~80 published studies (TB-500 / Thymosin Beta-4 fragment). Strongest record: cardiac muscle repair, dermal wound healing, anti-inflammatory. |
| Human clinical trials | ~0 published No published Phase 2+ human trial. Anecdotal patient reports only. | ~5 (full TB-4, not TB-500) Phase 1/2 trials exist for full Thymosin Beta-4 (RGN-352 cardiac, RGN-259 dry eye); the synthetic "TB-500" sold in the research market has not been formally tested. |
| Best-supported use case (in animals) | Tendon and ligament injury, gastric ulcer, gut barrier dysfunction | Acute cardiac muscle damage, dermal wound healing |
| Sport / WADA status | Not on prohibited list as of 2025–2026 WADA code | Prohibited (Section S2 — Peptide Hormones, Growth Factors). Banned in and out of competition. |
| FDA regulatory status (May 2026) | Removed from interim 503A bulks list Category 2 in April 2026; PCAC review July 2026; sold in research peptide market | Same — removed from Category 2 April 2026; PCAC review pending; sold in research market |
| Typical research-market price | ~$35–80 per 5mg vial | ~$40–90 per 5mg vial |
| Common stack name | "Wolverine" — pre-mixed BPC-157 + TB-500 in a single vial. No human study has ever tested the combination. | |
The animal evidence is real and worth taking seriously. It's also — importantly — not the same thing as human evidence. Here's what each peptide has actually been shown to do in controlled animal studies, distilled.
The BPC-157 literature is dominated by the work of Predrag Sikiric's research group in Croatia, which has published over 100 papers on the peptide since the 1990s. Across the body of work:
1. Tendon and ligament healing. Multiple controlled rat studies of Achilles tendon transection and medial collateral ligament rupture show faster healing time, increased tensile strength, and improved histology in BPC-157 treated animals vs. saline controls. Effect sizes are meaningful (often 30–50% faster recovery on histological endpoints).
2. Gastrointestinal protection. The original use case. BPC-157 prevents and accelerates healing of stomach ulcers in standard rat ulcer models (NSAID-induced, alcohol-induced). The mechanism is thought to be the same gut protection that gives the peptide its name.
3. Bone and joint. Some evidence in fracture-healing models showing accelerated bone-callus formation.
4. Neural recovery. Rat models of nerve crush injury and traumatic brain injury show some functional recovery improvement with BPC-157.
What's not in the literature: long-term safety data, large-animal data, or any controlled human trial demonstrating the effects translate.
The Thymosin Beta-4 literature is broader and more heterogeneous. Key replicated findings:
1. Cardiac muscle repair after infarction. Multiple animal studies of myocardial infarction (heart attack) show TB-4 reducing scar formation and improving cardiac function. This was the basis for the RGN-352 Phase 2 human trial program (cardiac surgery patients).
2. Dermal wound healing. Robust rodent and porcine wound-healing data. RGN-259 (a topical TB-4 formulation) has been in human trials for dry eye and corneal wounds.
3. Hair follicle effects. Some rodent data showing TB-4 promotes hair follicle development and migration. Marketed widely; mechanistically supported but not human-trialed.
4. Anti-inflammatory effects. Reduces pro-inflammatory cytokines (TNF-α, IL-6) in various injury models.
The "TB-500" specifically being sold in the research peptide market is the synthetic short fragment, not the full TB-4. Most of the impressive animal data is from the full protein. The fragment may retain the activity, but this is an extrapolation, not a verified equivalence.
The pre-mixed BPC-157 + TB-500 product, marketed as "Wolverine" by various research peptide vendors, is one of the most-purchased recovery stacks in the gray market. The marketing logic is that the two peptides hit different parts of the repair process. The clinical reality is more uncertain.
Mechanistic theory: BPC-157 promotes growth factor signaling and angiogenesis; TB-500 promotes cell migration and angiogenesis. The angiogenesis effect overlaps; the rest is complementary. In theory, you get both "more raw materials" (BPC-157) and "more workers" (TB-500) at the injury site.
Three honest points that the marketing pages don't include:
1. No human trial has ever compared the stack to either peptide alone. Not one. The marketing is built entirely on the individual ingredient profiles.
2. Doubling exposure doubles uncertainty. Both peptides have unknown long-term safety profiles in humans. Combining them doubles the unknown rather than adding two known things.
3. Cost-effectiveness is unclear. "Wolverine" combos typically cost more per unit than either peptide alone. If most of the benefit comes from one of the two, you're paying a premium for marginal additional effect.
The Wolverine stack is a vendor marketing concept rather than a clinical protocol. People who've used both peptides individually and then tried the combination report subjective benefit; this is anecdote, not evidence. If you're going to use either peptide, the clearest path is to use them one at a time so you know what's working and what isn't — and to remember that "subjectively feels better" is a notoriously unreliable signal in regenerative medicine because of placebo, time-since-injury, and coincident behavioral changes.
No comparison can replace a conversation with a sports medicine physician or orthopedic specialist who knows your specific injury. With that caveat, here's how thoughtful clinicians frame the choice:
BPC-157 has the stronger animal-model record specifically for these tissues. The mechanism (growth factor signaling + angiogenesis) lines up well with the demonstrated effects.
Lean: BPC-157TB-500 / Thymosin Beta-4 has the stronger animal data on wound closure and skin repair specifically. Topical formulations of full TB-4 have actually entered human trials (RGN-259).
Lean: TB-500TB-4 has more research on hair follicle migration. The actin-sequestration mechanism is more directly relevant to the cell movement involved in hair-follicle development.
Lean: TB-500 (cautiously)TB-500 is on the WADA prohibited list (Section S2). A single use ends competition eligibility for the standard window. BPC-157 is not on the prohibited list as of the 2026 WADA code, though this could change.
Lean: BPC-157 onlyThe Wolverine stack is the marketing answer. The honest answer is: try one peptide alone for a defined period, evaluate, then consider adding the other only if the first is genuinely inadequate.
Lean: Sequence, don't stackNeither has a published human clinical trial. If you need the strongest evidence base, the honest answer is to wait — or to pursue legitimate physical therapy and surgical interventions that have actual human RCT data behind them.
Lean: Neither (yet)1. Both are research-only in the U.S. No FDA-approved human dose exists. Quality varies dramatically between vendors — see our access guide on diligence for what to look for in a Certificate of Analysis.
2. Long-term safety is unstudied. The animal data covers weeks-to-months of exposure. What chronic use over years does to a person is genuinely unknown for both peptides.
3. If you're a competitive athlete, your sport's testing regime overrides everything else here. TB-500 in particular ends eligibility. Even BPC-157, while not currently prohibited, could be added to monitoring or banned in future WADA code revisions.
Animal-model literature, regulatory documentation, and sport governance — all primary or peer-reviewed:
Both peptides have full entries in the catalogue — mechanism, half-life, dosing, regulatory status, sources.
Open the Healing & Repair catalogue